Le Lézard
Classified in: Health
Subject: RCL

Public advisory - Bausch Health, Canada Inc. recalls all lots of Emerade epinephrine auto-injectors (0.3 mg and 0.5 mg strengths) due to possible device failure


OTTAWA, ON, May 5, 2023 /CNW/ -

Brand(s)
Emerade

Summary

Images

Emerade 0.3 mg (CNW Group/Health Canada)

Emerade 0.5 mg (CNW Group/Health Canada)

Affected products

Product

DIN

Lot Number

Expiration Date

Emerade 0.3 mg

02458446

Y0225B2A

2023-05-31

Emerade 0.3 mg

02458446

Z0076B1A

2023-08-30

Emerade 0.3 mg

02458446

Z0034B2C

2023-06-30

Emerade 0.3 mg

02458446

Z0198B3A

2024-10-31

Emerade 0.3 mg

02458446

Z0198B3B

2024-10-31

Emerade 0.5 mg

02458454

Y0225C1A

2023-05-31

Emerade 0.5 mg

02458454

Z0034C1A

2023-06-30

Emerade 0.5 mg

02458454

Z0076C2A

2023-08-30

Emerade 0.5 mg

02458454

Z0088C3A

2023-08-30

Emerade 0.5 mg

02458454

Z0153C2A

2024-08-31

Emerade 0.5 mg

02458454

Z0236C1C

2024-11-30

Emerade 0.5 mg

02458454

Z0088C3B

2023-08-31

Emerade 0.5 mg

02458454

Z0128C1B

2024-05-31

Emerade 0.5 mg

02458454

Z0153C2B

2024-08-31


Issue

Bausch Health, Canada Inc. is recalling all lots of Emerade epinephrine auto-injectors (0.3 mg and 0.5 mg) after testing by the company identified the potential risk that the auto-injector may fail to activate, or it may activate prematurely if dropped.

The affected lots of Emerade were distributed in Canada between April 2022 and May 2023.

Emerade auto-injectors are used to deliver an emergency treatment of epinephrine to patients who are at risk or have a history of serious allergic reactions (anaphylaxis). 

Failure of the auto-injector to activate may result in patients not receiving the required dose of epinephrine, leading to the worsening of symptoms of anaphylaxis which could be life-threatening.

Health Canada recognizes how important epinephrine auto-injectors are for people with life-threatening allergies. There are alternative epinephrine auto-injectors available in Canada. Ensuring Canadians can get the medicines they need is one of Health Canada's top priorities. A shortage of alternative products is not expected, but the Department will continue to actively monitor the supply situation.

What you should do

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 07:25
Prota Therapeutics' CEO Professor Mimi Tang has been honoured in the prestigious 2024 BioMelbourne Network Women in Leadership Awards. Professor Tang's exceptional work as a lead researcher for the Murdoch Children's Research Institute (MCRI) and her...

at 07:15
International medical imaging IT and Cybersecurity company Sectra's (STO: SECT B) digital pathology solution together with Leica Biosystems, Imaging, Inc.'s Aperio GT 450 DX have received a 510(k) clearance by the US Food & Drug Administration (FDA)....

at 07:11
Author C.A. Blake was 24 years old when her brother, Steve, committed suicide. She struggled with the feeling she wouldn't survive the pain of it. Growing up in a time where little to no coping skills were taught or offered, she traveled the path of...

at 07:05
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor...

at 07:05
Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective...

at 07:05
Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger...



News published on and distributed by: